These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20166790)

  • 1. Possible influence of variant of the P-glycoprotein gene (MDR1/ABCB1) on clinical response to guanfacine in children with pervasive developmental disorders and hyperactivity.
    McCracken JT; Aman MG; McDougle CJ; Tierney E; Shiraga S; Whelan F; Arnold LE; Posey D; Ritz L; Vitiello B; Scahill L
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):1-5. PubMed ID: 20166790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective open trial of guanfacine in children with pervasive developmental disorders.
    Scahill L; Aman MG; McDougle CJ; McCracken JT; Tierney E; Dziura J; Arnold LE; Posey D; Young C; Shah B; Ghuman J; Ritz L; Vitiello B
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):589-98. PubMed ID: 17069547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.
    Posey DJ; Puntney JI; Sasher TM; Kem DL; McDougle CJ
    J Child Adolesc Psychopharmacol; 2004; 14(2):233-41. PubMed ID: 15319020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.
    Scahill L; Chappell PB; Kim YS; Schultz RT; Katsovich L; Shepherd E; Arnsten AF; Cohen DJ; Leckman JF
    Am J Psychiatry; 2001 Jul; 158(7):1067-74. PubMed ID: 11431228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, prospective study of guanfacine in children with ADHD and tic disorders.
    Boon-yasidhi V; Kim YS; Scahill L
    J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S156-62. PubMed ID: 16856436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness.
    Scahill L
    CNS Drugs; 2009; 23 Suppl 1():43-9. PubMed ID: 19621977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Spencer TJ; Greenbaum M; Ginsberg LD; Murphy WR
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):501-10. PubMed ID: 19877974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guanfacine Use in Children With Down Syndrome and Comorbid Attention-Deficit Hyperactivity Disorder (ADHD) With Disruptive Behaviors.
    Capone GT; Brecher L; Bay M
    J Child Neurol; 2016 Jul; 31(8):957-64. PubMed ID: 26936058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guanfacine in children with autism and/or intellectual disabilities.
    Handen BL; Sahl R; Hardan AY
    J Dev Behav Pediatr; 2008 Aug; 29(4):303-8. PubMed ID: 18552703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder.
    Hunt RD; Arnsten AF; Asbell MD
    J Am Acad Child Adolesc Psychiatry; 1995 Jan; 34(1):50-4. PubMed ID: 7860456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of guanfacine extended release in the treatment of combined and inattentive only subtypes of attention-deficit/hyperactivity disorder.
    Sallee FR; Kollins SH; Wigal TL
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):206-14. PubMed ID: 22612526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guanfacine and guanfacine extended release: treatment for ADHD and related disorders.
    Posey DJ; McDougle CJ
    CNS Drug Rev; 2007; 13(4):465-74. PubMed ID: 18078429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial.
    Connor DF; Findling RL; Kollins SH; Sallee F; López FA; Lyne A; Tremblay G
    CNS Drugs; 2010 Sep; 24(9):755-68. PubMed ID: 20806988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does Guanfacine Extended Release Impact Functional Impairment in Children with Attention-Deficit/Hyperactivity Disorder? Results from a Randomized Controlled Trial.
    Stein MA; Sikirica V; Weiss MD; Robertson B; Lyne A; Newcorn JH
    CNS Drugs; 2015 Nov; 29(11):953-62. PubMed ID: 26547425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Huss M; McBurnett K; Cutler AJ; Hervás A; Bliss C; Gao J; Dirks B; Newcorn JH
    Eur Neuropsychopharmacol; 2019 Mar; 29(3):432-443. PubMed ID: 30064718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.
    Troost PW; Steenhuis MP; Tuynman-Qua HG; Kalverdijk LJ; Buitelaar JK; Minderaa RB; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):611-9. PubMed ID: 17069549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A; Huss M; Johnson M; McNicholas F; van Stralen J; Sreckovic S; Lyne A; Bloomfield R; Sikirica V; Robertson B
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.
    Schaich M; Kestel L; Pfirrmann M; Robel K; Illmer T; Kramer M; Dill C; Ehninger G; Schackert G; Krex D
    Ann Oncol; 2009 Jan; 20(1):175-81. PubMed ID: 18687982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Polanczyk G; Zeni C; Genro JP; Guimarães AP; Roman T; Hutz MH; Rohde LA
    Arch Gen Psychiatry; 2007 Feb; 64(2):218-24. PubMed ID: 17283289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.